| Symbol | DCTH |
|---|---|
| Name | DELCATH SYSTEMS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 1633 BROADWAY,SUITE 22C, NEW YORK, New York, 10019, United States |
| Telephone | +1 212 489-2100 |
| Fax | — |
| — | |
| Website | https://www.delcath.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000872912 |
| Description | Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firms product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Additional info from NASDAQ: |
(30% Negative) DELCATH SYSTEMS, INC. (DCTH) Reports Q2 2026 Financial Results
Read moreDelcath Systems Reports First Quarter 2026 Results and Business Highlights
Read moreDelcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Read moreDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Read moreNew Form DEFA14A - DELCATH SYSTEMS, INC. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001628280-26-022950 <b>Size:</b> 299 KB
Read moreNew Form DEF 14A - DELCATH SYSTEMS, INC. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001628280-26-022948 <b>Size:</b> 2 MB
Read moreDelcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Read morePennell Sandra 🟢 acquired 5.5K shares of DELCATH SYSTEMS, INC. (DCTH) at $9.04 Transaction Date: Mar 06, 2026 | Filing ID: 000006
Read more(19% Negative) DELCATH SYSTEMS, INC. (DCTH) Announces Delay in Society Trials for Metastatic Uveal Melanoma QUEENSBURY Due to Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01728051 | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With … | — | Metastatic Liver Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07281924 | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis | Phase1 | Metastatic Melanoma | Recruiting | 2026-05-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT06875128 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given … | Phase2 | Metastatic Breast Cancer in the Liver | Recruiting | 2026-01-29 | 2029-08-01 | ClinicalTrials.gov |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastat… | Phase2 | Metastatic Uveal Melanoma | Recruiting | 2025-12-31 | 2030-12-01 | ClinicalTrials.gov |
| NCT06607458 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given … | Phase2 | Refractory Metastatic Colorectal Cancer | Recruiting | 2025-08-05 | 2027-10-01 | ClinicalTrials.gov |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (H… | Phase3 | Metastatic Ocular Melanoma | Unknown | 2022-06-10 | 2024-03-01 | ClinicalTrials.gov |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intra… | Phase2 | Bile Duct Cancer | Unknown | 2018-04-10 | 2023-05-01 | ClinicalTrials.gov |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma | Phase3 | Melanoma, Ocular | Completed | 2016-02-01 | 2023-08-15 | ClinicalTrials.gov |
| NCT03266042 | Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment o… | — | Hepatic Malignant Neoplasm Primary Non-Resectable | Unknown | 2016-01-14 | 2020-02-01 | ClinicalTrials.gov |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by… | Phase2 | Hepatocellular Carcinoma (HCC) | Withdrawn | 2014-10-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With U… | Phase2 | Hepatocellular Carcinoma | Terminated | 2014-06-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Trea… | Phase3 | Intraocular Melanoma | Completed | 2006-02-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00096083 | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patie… | Phase2 | Cancer | Completed | 2004-09-01 | 2012-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Percutaneous Hepatic Perfusion | Other | Preclinical | Metastatic Liver Cancer | NO_LONGER_AVAILABLE | NCT01728051 |
| Melphalan | Other | Preclinical | Metastatic Liver Cancer | NO_LONGER_AVAILABLE | NCT01728051 |
| Sorafenib | Other | Phase PHASE2 | Hepatocellular Carcinoma (HCC) | WITHDRAWN | NCT02406508 |
| Melphalan/HDS | Other | Phase PHASE2 | Hepatocellular Carcinoma (HCC) | WITHDRAWN | NCT02406508 |
| Cisplatin and Gemcitabine | Other | Phase PHASE2 | Bile Duct Cancer | UNKNOWN | NCT03086993 |
| Melphalan/HDS | Other | Phase PHASE2 | Bile Duct Cancer | UNKNOWN | NCT03086993 |
| Melphalan | Other | Phase PHASE2 | Hepatocellular Carcinoma | TERMINATED | NCT02415036 |
| Delcath Hepatic Delivery System | Other | Phase PHASE2 | Hepatocellular Carcinoma | TERMINATED | NCT02415036 |
| Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) | Other | Phase PHASE3 | Metastatic Ocular Melanoma | UNKNOWN | NCT05022901 |
| Melphalan/HDS | Other | Phase PHASE3 | Melanoma, Ocular | COMPLETED | NCT02678572 |
| Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) | Other | Phase PHASE2 | Metastatic Breast Cancer in the Liver | RECRUITING | NCT06875128 |
| Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) | Other | Phase PHASE2 | Metastatic Breast Cancer in the Liver | RECRUITING | NCT06875128 |
| Trifluridine-tipiracil plus Bevacizumab Alone | Other | Phase PHASE2 | Refractory Metastatic Colorectal Cancer | RECRUITING | NCT06607458 |
| Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab | Drug | Phase PHASE2 | Refractory Metastatic Colorectal Cancer | RECRUITING | NCT06607458 |
| Melphalan | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Tebentafusp | Other | Phase PHASE2 | Metastatic Uveal Melanoma | RECRUITING | NCT07276386 |
| Melphalan/HDS (Percutaneous Hepatic Perfusion) | Other | Phase PHASE2 | Metastatic Uveal Melanoma | RECRUITING | NCT07276386 |
| Nivolumab and Relatlimab | DRUG | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| Tebentafusp | DRUG | Phase PHASE2 | Metastatic Uveal Melanoma | RECRUITING | NCT07276386 |
| Melphalan/HDS (Percutaneous Hepatic Perfusion) | DRUG | Phase PHASE2 | Metastatic Uveal Melanoma | RECRUITING | NCT07276386 |
| Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) | DRUG | Phase PHASE2 | Metastatic Breast Cancer in the Liver | RECRUITING | NCT06875128 |
| Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) | DRUG | Phase PHASE2 | Metastatic Breast Cancer in the Liver | RECRUITING | NCT06875128 |
| Trifluridine-tipiracil plus Bevacizumab Alone | DRUG | Phase PHASE2 | Refractory Metastatic Colorectal Cancer | RECRUITING | NCT06607458 |
| Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab | DRUG | Phase PHASE2 | Refractory Metastatic Colorectal Cancer | RECRUITING | NCT06607458 |
| Cisplatin and Gemcitabine | DRUG | Phase PHASE2 | Bile Duct Cancer | UNKNOWN | NCT03086993 |
| Delcath Hepatic Delivery System | DEVICE | Phase PHASE2 | Hepatocellular Carcinoma | TERMINATED | NCT02415036 |
| Sorafenib | DRUG | Phase PHASE2 | Hepatocellular Carcinoma (HCC) | WITHDRAWN | NCT02406508 |
| Melphalan/HDS | DEVICE | Phase PHASE2 | Hepatocellular Carcinoma (HCC) | WITHDRAWN | NCT02406508 |
| Percutaneous Hepatic Perfusion | DEVICE | Preclinical | Metastatic Liver Cancer | NO_LONGER_AVAILABLE | NCT01728051 |
| Melphalan | DEVICE | Phase PHASE1 | Metastatic Melanoma | RECRUITING | NCT07281924 |
| hepatic artery embolization | PROCEDURE | Phase PHASE3 | Intraocular Melanoma | COMPLETED | NCT00324727 |
| systemic chemotherapy | DRUG | Phase PHASE3 | Intraocular Melanoma | COMPLETED | NCT00324727 |
| regional chemotherapy | DRUG | Phase PHASE3 | Intraocular Melanoma | COMPLETED | NCT00324727 |
| melphalan | DRUG | Phase PHASE3 | Intraocular Melanoma | COMPLETED | NCT00324727 |
| isolated perfusion | DRUG | Phase PHASE2 | Cancer | COMPLETED | NCT00096083 |